Латвія - латвійська - Zāļu valsts aģentūra

wörwag pharma gmbh & co.kg, germany - duloksetīns - zarnās šķīstošā kapsula, cietā - 60 mg

Європейський Союз - латвійська - EMA (European Medicines Agency)

mylan ireland limited - rivaroxaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antitrombotiskie līdzekļi - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Європейський Союз - латвійська - EMA (European Medicines Agency)

viatris limited - pirfenidons - idiopathic pulmonary fibrosis; lung diseases; respiratory tract diseases - imūnsupresanti - pirfenidone viatris is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (ipf).

Латвія - латвійська - Zāļu valsts aģentūra

uab valentis, lithuania - povidons, jodēts - uz ādas lietojams šķīdums - 100 mg/ml

Латвія - латвійська - Zāļu valsts aģentūra

fresenius kabi ab, sweden - soiae naftas raffinatum, triglycerida saturata mediju, zivju eļļa omega-3 taukskābes, bagāts, olīveļļa raffinatum - emulsija infūzijām - 20%

Латвія - латвійська - Zāļu valsts aģentūra

correvio, france - tirofibāns - koncentrāts infūziju šķīduma pagatavošanai - 250 μg/ml

Латвія - латвійська - Zāļu valsts aģentūra

as Ņižfarm pārstāvniecība, latvia - hidrokortizona acetāts - ziede - 10 mg/g

Латвія - латвійська - Pārtikas un veterinārais dienests, Zemkopības ministrija

intervet international b.v., nīderlande - embutramide, mebezonium iodide, tetracaine hydrohchloride - šķīdums injekcijām - dekoratīvie sīkdzīvnieki; kaķi; lielie dzīvnieki; putni; suņi

Європейський Союз - латвійська - EMA (European Medicines Agency)

ucb pharma s.a.   - fenfluramine hydrochloride - epilepsies, myoclonic - antiepileptics, - treatment of seizures associated with dravet syndrome as an add-on therapy to other antiepileptic medicines for patients 2 years of age and older. fintepla is indicated for the treatment of seizures associated with dravet syndrome and lennox-gastaut syndrome as an add-on therapy to other anti-epileptic medicines for patients 2 years of age and older.

Латвія - латвійська - Zāļu valsts aģentūra

pharmaswiss ceska republika s.r.o., czech republic - petidīna hidrohlorīds - Šķīdums injekcijām - 50 mg/ml